DocDollars

Supernus Pharmaceuticals, Inc.

MD · United States · Reporting entity ID 100000011150

Total reported 2019–2025
$55.7M
#158 of 2,960 reporting companies — 0.1% of all reported industry payments
$19.5M in general payments across 354,972 records, plus $36.2M in research funding across 5,447 records.

How it breaks down

General payments $19,542,301
Research funding $36,204,624

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Supernus Pharmaceuticals, Inc. reported $55.7M to US doctors and teaching hospitals from 2019 to 2025, ranking #158 of 2,960 reporting companies. 65% of that was research funding and 35% general payments such as consulting, speaking, food and travel. 354,972 general payment records and 5,447 research records were filed.

Common questions about Supernus Pharmaceuticals, Inc.

How much has Supernus Pharmaceuticals, Inc. paid US doctors?

Supernus Pharmaceuticals, Inc. reported $55,746,925 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $19,542,301 in general payments, $36,204,624 in research funding.

How does Supernus Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #158 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Supernus Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.